Tevogen Bio (TVGN) said Monday it expects revenue of nearly $1 billion for its specialty care pipeline in the launch year.
The company estimates its cumulative specialty care revenue over five years to range between $18 billion and $22 billion.
Price: 1.7500, Change: -0.05, Percent Change: -2.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。